Please set your featured image
OGT expands its portfolio of Cytocell pathology FISH probes
Oxford Gene Technology (OGT), the molecular genetics company based at Begbroke Science Park, is extending its portfolio of Cytocell® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH.
The addition of eight new pathology probes highlights OGT’s ongoing commitment to the FISH market following its acquisition of Cytocell in June 2014. Dr Mike Evans, CEO of OGT commented: “We are delighted to be expanding our already extensive portfolio of Cytocell FISH probes. Through our exceptional probe quality and range, plus our dedicated support team, we believe that we offer the best value FISH products available.”
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market.
For more information on the Company, please visit their website